AIMS: This study was designed to characterize paediatric pharmacokinetics and central nervous system exposure of flurbiprofen. METHODS: The pharmacokinetics of flurbiprofen were studied in 64 healthy children aged 3 months to 13 years, undergoing surgery with spinal anaesthesia. Children were administered preoperatively a single dose of flurbiprofen intravenously as prodrug (n= 27) or by mouth as syrup (n= 37). A single cerebrospinal fluid (CSF) sample (n= 60) was collected at the induction of anaesthesia, and plasma samples (n= 304) before, during and after the operation (up to 20 h after administration). A population pharmacokinetic model was built using the NONMEM software package. RESULTS: Flurbiprofen concentrations in plasma were well described by a three compartment model. The apparent bioavailability of oral flurbiprofen syrup was 81%. The estimated clearance (CL) was 0.96l h(-1) 70 kg(-1) . Age did not affect the clearance after weight had been included as a covariate. The estimated volume of distribution at steady state (V(ss) ) was 8.1 l 70 kg(-1) . Flurbiprofen permeated into the CSF, reaching concentrations that were seven-fold higher compared with unbound plasma concentrations. CONCLUSIONS: Flurbiprofen pharmacokinetics can be described using only weight as a covariate in children above 6months, while more research is needed in neonates and in younger infants.
AIMS: This study was designed to characterize paediatric pharmacokinetics and central nervous system exposure of flurbiprofen. METHODS: The pharmacokinetics of flurbiprofen were studied in 64 healthy children aged 3 months to 13 years, undergoing surgery with spinal anaesthesia. Children were administered preoperatively a single dose of flurbiprofen intravenously as prodrug (n= 27) or by mouth as syrup (n= 37). A single cerebrospinal fluid (CSF) sample (n= 60) was collected at the induction of anaesthesia, and plasma samples (n= 304) before, during and after the operation (up to 20 h after administration). A population pharmacokinetic model was built using the NONMEM software package. RESULTS:Flurbiprofen concentrations in plasma were well described by a three compartment model. The apparent bioavailability of oral flurbiprofen syrup was 81%. The estimated clearance (CL) was 0.96l h(-1) 70 kg(-1) . Age did not affect the clearance after weight had been included as a covariate. The estimated volume of distribution at steady state (V(ss) ) was 8.1 l 70 kg(-1) . Flurbiprofen permeated into the CSF, reaching concentrations that were seven-fold higher compared with unbound plasma concentrations. CONCLUSIONS:Flurbiprofen pharmacokinetics can be described using only weight as a covariate in children above 6months, while more research is needed in neonates and in younger infants.
Authors: Craig R Lee; John A Pieper; Reginald F Frye; Alan L Hinderliter; Joyce A Blaisdell; Joyce A Goldstein Journal: Eur J Clin Pharmacol Date: 2003-02-26 Impact factor: 2.953
Authors: B Bannwarth; F Lapicque; F Pehourcq; P Gillet; T Schaeverbeke; C Laborde; J Dehais; A Gaucher; P Netter Journal: Br J Clin Pharmacol Date: 1995-09 Impact factor: 4.335
Authors: Hannu Kokki; Elina Kumpulainen; Marko Lehtonen; Merja Laisalmi; Marja Heikkinen; Jouko Savolainen; Jarkko Rautio Journal: Pediatrics Date: 2007-10 Impact factor: 7.124
Authors: Laurie P Volak; Michael J Hanley; Gina Masse; Suwagmani Hazarika; Jerold S Harmatz; Vladimir Badmaev; Muhammed Majeed; David J Greenblatt; Michael H Court Journal: Br J Clin Pharmacol Date: 2013-02 Impact factor: 4.335
Authors: Victoria C Ziesenitz; Tatjana Welzel; Madelé van Dyk; Patrick Saur; Matthias Gorenflo; Johannes N van den Anker Journal: Paediatr Drugs Date: 2022-09-02 Impact factor: 3.930
Authors: Zoe Kane; Silke Gastine; Christina Obiero; Phoebe Williams; Sheila Murunga; Johnstone Thitiri; Sally Ellis; Erika Correia; Borna Nyaoke; Karin Kipper; John van den Anker; Mike Sharland; James A Berkley; Joseph F Standing Journal: J Antimicrob Chemother Date: 2021-06-18 Impact factor: 5.790
Authors: Jerome Mertens; Kathrin Stüber; Patrick Wunderlich; Julia Ladewig; Jaideep C Kesavan; Rik Vandenberghe; Mathieu Vandenbulcke; Philip van Damme; Jochen Walter; Oliver Brüstle; Philipp Koch Journal: Stem Cell Reports Date: 2013-12-05 Impact factor: 7.765